Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.

@article{Tandon2011DualEG,
  title={Dual epidermal growth factor receptor (EGFR)/insulin-like growth factor-1 receptor (IGF-1R) inhibitor: a novel approach for overcoming resistance in anticancer treatment.},
  author={Ruchi Tandon and Shweta Kapoor and Shireen Vali and Vinitha Senthil and Dr. A. Nithya and Raman Venkataramanan and Ashish Sharma and Anay Talwadkar and Abhijit Ray and Pradip Kumar Bhatnagar and Sunanda Ghosh Dastidar},
  journal={European journal of pharmacology},
  year={2011},
  volume={667 1-3},
  pages={
          56-65
        }
}
Small molecule inhibitors of epidermal growth factor receptors (EGFR) have been found to show a good initial response in cancer patients but during the course of treatment, patients develop resistance after a few weeks of time. Development of secondary mutations or over-activation of insulin like growth factor (IGF-1R) pathway are a few of the several mechanisms proposed to explain the resistance. To study the effect of dual inhibition of EGFR and IGF-1R in overcoming the resistance, three… CONTINUE READING
Highly Cited
This paper has 27 citations. REVIEW CITATIONS

Citations

Publications citing this paper.
Showing 1-10 of 17 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Suppression of signal transducer and activator of transcription 3 activation by butein inhibits growth of human hepatocellular carcinoma in vivo.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2011
View 1 Excerpt

IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.

Clinical cancer research : an official journal of the American Association for Cancer Research • 2007
View 2 Excerpts